Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

La Revue de medecine interne - 1 Dec 2006

Loriot M-A, Beaune P

Abstract excerpt

INTRODUCTION: Vitamin K epoxide reductase complex subunit I (VKORC1) is a key enzyme in the vitamin K cycle, cofactor required for the activation of vitamin K-dependent clotting factors. EXEGESIS: VKORC1 recycles vitamin K 2,3 epoxide back to active vitamin K hydroquinone, an important factor for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Algorithms
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance

Share to Mixed Function Oxygenases

Share to Polymorphism, Genetic

Share to Vitamin K

Share to Vitamin K Epoxide Reductases

Source

Identifiers

PMID: 17070618
DOI: 10.1016/j.revmed.2006.09.004

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-17070618-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].PMID 17070618Read ↗

VKORC1 and the vitamin K cycle.Semantic proximity Read ↗

Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency.Semantic proximity Read ↗

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].Semantic proximity Read ↗

Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study.Semantic proximity Read ↗

Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.Semantic proximity Read ↗

Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.Semantic proximity Read ↗

Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.Semantic proximity Read ↗

Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.Semantic proximity Read ↗

Structural Modeling Insights into Human VKORC1 Phenotypes.Semantic proximity Read ↗

Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism as determinant of differences in Covid-19-related disease severity.Semantic proximity Read ↗

A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme.Semantic proximity Read ↗

The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.